Brain gliomas are highly malignant tumors for which there are currently no effective treatments except for chemoradiotherapy and surgery. B2068’s design target 1 is a completely new target protein which is highly expressed in the brain glioma, with its expression positively correlated to the degree of tumor malignancy. B2068 produces a targeted killing effect on the tumor cells by targeting this protein. Design target 2 activates immune cells by simulating immune co-stimulators to improve the tumor micro-environment. It works in conjunction with target 1 to produce a synergistic anti-tumor effect.